David A. Siegel Ikena Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 157,400 shares of IKNA stock, worth $218,785. This represents 0.0% of its overall portfolio holdings.
Number of Shares
157,400
Previous 202,100
22.12%
Holding current value
$218,785
Previous $349,000
26.07%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IKNA
# of Institutions
55Shares Held
31.9MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$6.98 Million1.36% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$5.69 Million2.87% of portfolio
-
Bvf Inc San Francisco, CA4.01MShares$5.57 Million0.25% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.59MShares$4.98 Million3.65% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.92 Million0.16% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $50.4M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...